Haemonetics Co. (NYSE:HAE) SVP Jacqueline Scanlan sold 195 shares of the firm’s stock in a transaction on Monday, June 7th. The stock was sold at an average price of $55.09, for a total value of $10,742.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Jacqueline Scanlan also recently made the following trade(s):
- On Monday, May 17th, Jacqueline Scanlan sold 102 shares of Haemonetics stock. The stock was sold at an average price of $55.97, for a total value of $5,708.94.
Shares of NYSE:HAE opened at $58.41 on Friday. Haemonetics Co. has a 12-month low of $49.26 and a 12-month high of $142.11. The firm has a fifty day moving average of $72.55. The stock has a market cap of $2.98 billion, a P/E ratio of 37.68, a PEG ratio of 2.01 and a beta of 0.36. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.74 and a quick ratio of 1.46.
Institutional investors have recently bought and sold shares of the company. Van ECK Associates Corp acquired a new stake in shares of Haemonetics in the 1st quarter worth $28,000. Meeder Asset Management Inc. boosted its position in shares of Haemonetics by 7,350.0% in the 1st quarter. Meeder Asset Management Inc. now owns 298 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 294 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Haemonetics in the 1st quarter worth $35,000. Berman Capital Advisors LLC acquired a new stake in shares of Haemonetics in the 4th quarter worth $47,000. Finally, IronBridge Private Wealth LLC acquired a new stake in shares of Haemonetics in the 4th quarter worth $119,000. 97.34% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have commented on HAE shares. Raymond James raised their price objective on Haemonetics from $145.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, February 12th. JMP Securities reduced their price objective on Haemonetics from $110.00 to $90.00 and set a “market outperform” rating on the stock in a report on Thursday, May 20th. CJS Securities upgraded Haemonetics from a “market perform” rating to an “outperform” rating in a report on Friday, May 14th. Jefferies Financial Group reduced their price objective on Haemonetics from $105.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, May 14th. Finally, Needham & Company LLC cut their price target on Haemonetics from $158.00 to $108.00 and set a “buy” rating on the stock in a report on Monday, April 19th. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $101.29.
Haemonetics Company Profile
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
See Also: Recession
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.